Improved melanoma suppression with target-delivered TRAIL and Paclitaxel by a multifunctional nanocarrier.
Abstract
Malignant melanoma, a highly dangerous type of skin cancer, is usually resistant to pro-apoptosis agents such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) due to low death receptor expression levels. After verifying combination of chemotherapy drug paclitaxel (PTX) and TRAIL could significantly enhance their anti-melanoma effects, we developed a liposomal melanoma target-delivery system with tumor microenvironment...
Paper Details
Title
Improved melanoma suppression with target-delivered TRAIL and Paclitaxel by a multifunctional nanocarrier.
Published Date
Sep 10, 2020
Volume
325
Pages
10 - 24
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History